Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.
Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.
ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.
This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.
Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.
ICON (ICLR) reported its Q4 and full-year 2024 results, with Q4 net business wins of $2,413 million and a book-to-bill ratio of 1.18. Full-year net business wins reached $9,974 million with a 1.20 book-to-bill ratio. The company's closing backlog grew to $24.7 billion, up 8.3% year-over-year.
Q4 revenue was $2,041.1 million, down 1.2% year-over-year, while full-year revenue increased 2.0% to $8,282 million. Q4 adjusted EBITDA was $422.6 million (20.7% of revenue), and full-year adjusted EBITDA reached $1,735.8 million (21.0% of revenue). The company achieved $1.1 billion in free cash flow for 2024 and maintained a net debt of $2.9 billion.
ICON repurchased $400 million worth of stock in Q4 at an average price of $217 and authorized a new $750 million share repurchase program. The company reaffirmed its 2025 revenue guidance of $8,050-$8,650 million and adjusted EPS guidance of $13.00-$15.00.
ICON plc (NASDAQ: ICLR) announced the expansion of its artificial intelligence (AI) tools portfolio to enhance clinical trial processes. The company has established an AI Centre of Excellence, supported by an AI Governance Committee, to develop and deploy AI solutions.
The new solutions include: iSubmit for automated document management, Mapi Research Trust COA for clinical outcome assessments, FORWARD+ for resource management, Study Start-up Site Contracts for contract drafting, and OMR AI Navigation Assistant for operational metrics analysis.
ICON received an Enterprise Ireland grant to further enhance its AI capabilities. A recent company survey revealed that 13% of biopharma companies face challenges in systematically incorporating AI technologies despite their heavy use in single development programs.
ICON plc (NASDAQ: ICLR), a healthcare intelligence and clinical research organization, has scheduled its fourth quarter and full year 2024 earnings release for Wednesday, February 19, 2025, after market close. The company will host a conference call and webcast to discuss the financial results on Thursday, February 20, 2025, at 8:00am ET. A replay of the webcast will be available approximately one hour after the call concludes. Investors can access the webcast through the Events section of ICON's investor relations website.
ICON plc (NASDAQ: ICLR) has released its financial guidance for 2025, projecting revenue between $8,050 - $8,650 million, representing approximately 1% growth at the midpoint compared to 2024. The company expects adjusted earnings per share between $13.00 - $15.00, flat compared to 2024's guidance midpoint.
The company reaffirmed its 2024 guidance with revenue between $8,260 - $8,300 million and adjusted earnings per share of $13.90 - $14.10. ICON repurchased $400 million worth of stock in Q4 2024 at an average price of $217, bringing the full-year 2024 repurchase total to $500 million.
CEO Dr. Steve Cutler noted that ICON faces challenges from cautious spending by biopharma customers and expects a transition period with headwinds from its top two customers. However, growth in strategic partnerships is expected to partially offset these challenges. The company reported a trailing twelve-month book-to-bill ratio of 1.2 times in Q4.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has released a survey of 120+ biotech and pharma professionals focusing on neurodegenerative disorder treatments. Despite recent successes in Alzheimer's disease treatments, challenges in neurodegenerative trials persist. ICON's new whitepaper, ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s R&D', highlights the potential of underutilized trial methodologies.
Biomarkers are important for early identification of trial participants. 97% of respondents use biomarkers, and 59% leverage AI for biomarker detection. However, biomarkers are not fully optimized, potentially making trials longer and costlier. Innovative trial designs are underused, with only 28% using adaptive designs, 22% using historic controls, and 19% utilizing master protocols.
Peter Schueler, MD, Senior VP at ICON, emphasizes the complexity of neurodegenerative research and the need for cost-effective and validated tools. Despite challenges, 87% of respondents plan diversified R&D investments, and AI is predominantly used in early development stages. Only 29% see collaboration as a key acceleration factor. Further industry engagement is essential to replicate and improve upon recent clinical successes.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organisation, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Steve Cutler, CEO of ICON plc, is scheduled to present at the conference on Tuesday, January 14, 2025 at 3:45pm PST. The company will provide updates regarding any changes to the event and access to the live webcast through the Investor section of their website under the Events tab.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organisation, has received multiple prestigious awards in late 2024. The company ranked highest among clinical research organizations on TIME Magazine's 2024 World's Best Companies list and secured the 57th position on the 2025 World's Best Companies in Sustainable Growth list.
Notable achievements include winning the Scrip award for Best Contract Research Organisation for the fifth time in eight years, and the Best Practices Recognition award from the Frost and Sullivan Institute. Individual recognition went to executives Barry Balfe (PharmaVoice 100 List) and Rose Kidd (Businesswoman Award), while Alexander Murray was named IRT Young Professional 2024.
The company also excelled in creative and digital marketing, winning multiple awards including Health + Wellness awards, MarCom Awards, and Stevie® Awards for various clinical study materials and technological innovations.
ICON plc (NASDAQ: ICLR) has appointed Barry Balfe as Chief Operating Officer (COO). Balfe, a 20-year veteran of the company, has served in various leadership roles across full service and functional solutions. He will continue to report to CEO Steve Cutler.
The appointment leverages Balfe's extensive experience in operational excellence, quality, and delivery. His track record includes successfully leading ICON's largest division and developing strategic customer partnerships that have contributed to the company's growth. In his new role, Balfe will focus on driving further organizational growth and enhancing ICON's position as a healthcare intelligence partner.
ICON plc (NASDAQ: ICLR) has released findings from a global survey of 101 biotech and pharma professionals regarding AI and digital innovation adoption in clinical research. The survey reveals sustained optimism about digital tools, with an 82% agreement on improved R&D investment returns and 76% on enhanced product safety and efficacy.
Key findings show a 34% average increase in digital tools investment over the past five years, with 88% of respondents planning further increases in the next two years. However, implementation remains selective, with 70% of organizations either piloting or selectively using AI, and only 13% having fully implemented comprehensive AI programs.
The survey identifies challenges in broader adoption, including concerns about patient safety, data integrity, and regulatory compliance. Despite these challenges, ICON emphasizes the need for comprehensive strategic approaches to maximize digital technologies in R&D.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has announced its participation in the upcoming Jefferies London Healthcare Conference. Dr. Steve Cutler (CEO) and Nigel Clerkin (CFO) will deliver a presentation on Thursday, November 21, 2024 at 8:00am GMT. Updates regarding the event and webcast links will be available in the Investor section of ICON's website under 'Events'.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
What services does ICON plc provide?
Where is ICON plc headquartered?
What is ICON's role in pharmaceutical development?
Does ICON offer standalone and integrated services?
What is pharmacovigilance, and does ICON provide it?
What industries does ICON serve?
What makes ICON a leader in its industry?
How can I stay updated on ICON's latest news and developments?
What are some of ICON's ancillary services?
What type of clients does ICON work with?
